UCLA is expanding access to the Ga-68... - Advanced Prostate...

Advanced Prostate Cancer
10,736 members12,856 posts

UCLA is expanding access to the Ga-68-PSMA-11 PET scan


They have announced expanded access to the PET scan until the FDA approves it, hopefully by this summer. The PET scan is available to all patients with diagnosed prostate cancer. The prices differ slightly according to the patient's current situation. The current wait time for appointments is 2-3 weeks.

Expanded Access Protocol (out-of-pocket cost = $2,977)

• Recurrent after prostatectomy (PSA≥0.2) or prostate radiation (PSA≥ nadir+2.0)

• Patients with a intermediate–risk or high–risk or locally advanced diagnosis, planning on prostatectomy

"Bucket" Protocol (out-of-pocket cost = $2,784)

• Newly diagnosed with localized prostate cancer, any risk category, planning on radiation or any other treatment

• Patients with Nodal (N1) or distant metastases (M1) who aren't planning prostatectomy

• Recurrent after ablation therapy (e.g., HIFU, Tulsa, cryo, FLA, etc.)

See the following for contact details:


14 Replies

The slight difference in pricing seems a bit strange.

Are you aware of the rational?

Tall_Allen in reply to cesanon

I have no idea why the bucket protocol is $200 less

Wow! This is great news! Thank you, TA, for posting it.

My 2nd opinion Dr worked at UCLA and told me I could get one about $1000 cheaper than that out of pocket back on October 2019. I never did follow through as none of my doctors thought it was worth it out of pocket as it would not change my treatment. My local imaging place quoted me $6500.00 Maybe insurance will pay for it when it comes up again.

I have been there twice. At that time it was $2600.

Had it one year ago for $2,600. If I'd done it this year, looks like I would have been in the high-risk category (t3b) and paid $2,977. Maybe this option uses more tracer, and thus costs more.

Thank you! Indeed, after cancelling an appointment 2 weeks ago, UCLA contacted us the following week to reschedule.

Good news. Another tool in the tool box.

Australia has had free access to Psa Ga68 PET + CT scans since 2015, at a price of usd $434,

based on aud $1.00 worth only usd $0.62. I have no idea why such differences exist between national currencies, probably to prop up the uber rich at Wall Street.

There is no Medicare rebate here yet for this scan, but I can see just how sick the medical system in USA is where an essential and useful type of scan costs usd $2,977. I've had about 6 Psma Ga68 scans so far, and they have been very good in showing my Pca status, results of treatments and thus removes the guesswork by doctors.

But I may have been reluctant to pay usd $17,862 for those 6 scans.

If these scans are so expensive I can only wonder what the costs are for other treatments compared to Australian cost. I've often said an option for men where chemo has failed is Lu177, yet to be approved in USA, but when it is approved, my guess is that it will be horrendously expensive in USA. Lu177 costs usd $5,952.00 for each infusion, and usually 4 are needed.

Will Americans be charged usd $40,000 for each infusion?

Its no wonder than that some Pca patients are flying to Australia to get treated by Theranostics Australia in Perth or Sydney.

Some Pca patients have also flown to Germany for Lu177, where the treatment was invented, and I don't know how their costs compare with ours.

However, international flights are shut down by C19 and there would now be no access to LU177 for many in USA because FDA is so slow approving new treatments, one reason being that they don't want doctors to suffer financially giving existing treatments which fail more than Lu177.

I'm glad I live in Australia and not in US just for the medical care structure we have.

Time I went for a nice long cycle ride across town for lunch and a coffee. Its a nice autumn day here, and I hope you all are not too badly affected by C19.

It seems I have little to fear if I go for a long cycle alone, like I have been doing for many years.

Patrick Turner.

This is wonderful news! Ed didn't do the 68 Ga, but I did price it at UCLA @ $2600 as a trial in late 2018. I found the F-18 DCFPyL at Stanford, last patient of Phase II trial, for no charge to the patient, so elected to do that one (DCFPyL did find the reoccurrence). Previously had done Axumin, C-11 acetate (trial in Phoenix @ $3,000 out of pocket), and later, the C-11 choline at Mayo Rochester. Another tool without the exclusions of the trials or the cost of the C-11 choline is so exciting.

He did them all! DCFPyL is the best, followed by Ga-68-PSMA-11. They both completed their initial trials at around the same time, so I expect the FDA will approve both at the same time. Axumin comes in third and Blue Earth Diagnostics has started trials of a new F18 rhPSMA PET indicator that they hope will outperform DCFPyL. There are also early trials of other PSMA indicators like Ga-68-PSMA-R2 and F18-PSMA-1007. This is a very active field, and the competition is good for the patient. The C-11 PETs (choline and acetate) are an "also ran," and Mayo seems to be really pushing it to recoup their investment.

Any thoughts on which PSMA diagnostic PET ligand will be the easiest for community RT departments to adapt? I understand there are potentially commercially available Ge-68 "generators" to generate isotope from Ga-68 without needing an in community cyclotron, etc. for short half-life isotopes. Such considerations may affect availability, once approved, to community hospitals.

F18 will always be preferable to Ga68 types.

Great news TA. Thanks for posting.

You may also like...